trending Market Intelligence /marketintelligence/en/news-insights/trending/GHiIJqRDfCXFbfNcZG5Xwg2 content esgSubNav
In This List

Acorda Therapeutics refiles drug application for Parkinson's treatment

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Acorda Therapeutics refiles drug application for Parkinson's treatment

Acorda Therapeutics Inc. resubmitted its new drug application with the U.S. Food and Drug Administration for Inbrija, a Parkinson's disease treatment.

The drug is indicated to treat patients experiencing so-called off-periods — when the effects of a medication start to wear off in between doses — or the re-emergence of Parkinson's symptoms.

Acorda said the resubmission contains information on the two concerns raised by the FDA, along with additional requested data, detailed in the agency's refusal to file letter.

The company said it expects to be notified by the FDA within 74 days if the submission is complete and permitted to undergo a full review.